Specify a stock or a cryptocurrency in the search bar to get a summary
Alzinova AB
ALZAlzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer's disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden. Address: Pepparedsleden 1, Mölndal, Sweden, 431 83
Analytics
WallStreet Target Price
57.16 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALZ
Dividend Analytics ALZ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALZ
Stock Valuation ALZ
Financials ALZ
Results | 2019 | Dynamics |